Comparação entre o Guideline 2021 e 2019 do Carcinoma Basocelular

Abstract

Basal cell carcinoma (BCC) accounts for about 75% of non-melanoma skin cancers. The doctor must know how to identify it and also seek updates on its treatment, diagnosis and prognosis, and can be guided by the guidelines.The physician must know how to identify it and also seek updates on treatments, diagnoses and prognoses, and this can be extracted from guidelines. Define what changes have occurred in the 2021 guideline compared to the last 2019 guideline, exposing these changes and guiding professionals with such updates in a simple and clear way. This is a literature review study. Several recommendations remained unchanged between the 2019 and 2021 Guidelines. The main changes were related to risk factors for recurrences and the diagnostic approach according to these factors.